Biotech Values

[DewDiligence]

ATR—Not a tax inversion, but a reshuffling to accomplish the same goal (flexibility in spending ex-US profits):

http://finance.yahoo.com/news/aptargroup-reports-highest-second-quarter-210000356.html

AptarGroup is in the process of implementing a legal entity reorganization for our non-U.S. subsidiaries that will allow greater financial flexibility in the future. As a result of this legal entity reorganization, the Company expects to record a one-time tax expense in the third quarter of approximately $3 million or $0.04 per share, which is not included in the guidance range given.

As the potential for tax inversions declines (due to legislation and/or fewer remaining suitable acquisition targets), I expect US-based multinational companies to engage in more of this kind of tax maneuvering.